Pfizer India (PFIZER) Q3 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter and nine months ended December 31, 2024, were reviewed and approved by the Board on January 31, 2025.

• Financials prepared in accordance with Indian Accounting Standards and SEBI regulations.

• No subsidiaries, associates, or joint ventures as of December 31, 2024.

Financial highlights

• Revenue from operations for Q3 FY25 was ₹588.59 crore, up from ₹537.99 crore in the previous quarter and ₹539.97 crore year-over-year.

• Net profit for Q3 FY25 stood at ₹158.35 crore, compared to ₹127.60 crore in the previous quarter and ₹129.98 crore year-over-year.

• Total income for the nine months ended December 31, 2024, was ₹1,817.11 crore, up from ₹1,751.92 crore year-over-year.

• Earnings per share (EPS) for Q3 FY25 was ₹34.61, compared to ₹27.89 in the previous quarter and ₹28.42 year-over-year.

Outlook and guidance

• Completion of the Thane property transaction is pending final approval from MIDC; no effect has been given in current financials.